Federal Register / Vol. 72, No. 141 / Tuesday, July 24, 2007 / Notices 40317 

purses inspected or x-rayed as they enter NIH 

buildings. For more information about the 

new security measures at NIH, please visit 

the Web site at http://www.nih.gov/about/ 

visitorsecurity.htm. 

Dated: July 12, 2007. 

Raynard S. Kington, 

Deputy Director, National Institutes of Health. 

[FR Doc. E7–14208 Filed 7–23–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicines; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the National Advsiory 

Council for Complementary and 

Alternate Medicine (NACCAM) meeting. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussion could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Complementary and Alternative 

Medicine. 

Date: September 5, 2007. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Open: 1 p.m. to 4:30 p.m. 

Agenda: Opening remarks by the Acting 

Director of National Center for 

Complementary and Alternative Medicine, 

presentation of a new research alternative, 

and other business of the Council. 

Place: National Institutes of Health, 

Neuroscience Building, 6001 Executive 

Boulevard, Conference Rooms C & D, 

Bethesda, MD 20882. 

Contact Person: Martin H. Goldrosen, 

Executive Secretary, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 401, Bethesda, MD 

20892, (301) 594–2014. 

The public comments session is scheduled 

from 4–4:30 p.m., but could change 

depending on the actual time spent on each 

agenda item. Each speaker will be permitted 

5 minutes for their presentation. Interested 

individuals and representatives of 

organizations are requested to notify Dr. 

Martin H. Goldrosen, National Center for 

Complementary and Alternative Medicine, 

NIH, 6707 Democracy Boulevard, Suite 401, 

Bethesda, Maryland, 20892, 301–594–2014, 

Fax: 301–480–9970. Letters of intent to 

present comments, along with a brief 

description of the organization represented, 

should be received no later than 5 p.m. on 

September 3, 2007. Only one representative 

of an organization may present oral 

comments. Any person attending the meeting 

who does not request an opportunity to speak 

in advance of the meeting may be considered 

for oral presentation, if time permits, and at 

the discretion of the Chairperson. In 

addition, written comments may be 

submitted to Dr. Martin H. Goldrosen at the 

address listed above up to ten calendar days 

(September 15, 2007) following the meeting. 

Copies of the meeting agenda and the 

roster of members will be furnished upon 

request by contacting Dr. Martin H. 

Goldrosen, Executive Secretary, NACCAM, 

National Center for Complementary and 

Alternative Medicine, National Institutes of 

Health, 6707 Democracy Boulevard, Suite 

401, Bethesda, Maryland 20892, 301–594–

2014, Fax 301–480–9970, or via e-mail at 

naccames@mail.nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

into the building by nongovernment 

employees. Persons without a government 

I.D. will need to show a photo I.D. and sign 

in at the security desk upon entering the 

building. 

Dated: July 17, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3587 Filed 7–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6Z), Title 5 

U.S.C., as amended. The contract 

proposals and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the contract proposals, the disclosure of 

which would constituet a clearly 

unwarranted invasion of personal 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

NIAID HIV/AIDS Scientific and Operations 

Support. 

Date: August 7, 2007. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Robert B. Moore, PhD, 

Health Scientist Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7202, Bethesda, MD 20892, 301 435–0050, 

mooreb@nhlbi.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.38, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: July 17, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3586 Filed 7–23–07; 8:45 am] 

BILLING CODE 4140–07–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Council on Drug 

Abuse. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

mstockstill on PROD1PC66 with NOTICES

40318 Federal Register / Vol. 72, No. 141 / Tuesday, July 24, 2007 / Notices 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Drug Abuse. 

Date: September 11–12, 2007. 

Closed: September 11, 2007, 3 p.m. to 5 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Open: September 12, 2007, 8:30 a.m. to 1 

p.m. 

Agenda: This portion of the meeting will 

be open to the public for announcements and 

reports of administrative, legislative and 

program developments in the drug abuse 

field. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: Teresa Levitin, PhD, 

Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

443–2755. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.drugabuse.gov/NACDA/ 

NACDAHome.html, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs. National 

Institutes of Health, HHS) 

Dated: July 16, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3584 Filed 7–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel, Knee 

Surgery Clinical Trial. 

Date: August 13, 2007. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 16, 16 Center Drive, Bethesda, MD 

20892, (Telephone Conference Call). 

Contact Person: Michael L. Bloom, PhD, 

MBA, Scientific Review Administrator, EP 

Review Branch, NIH/NIAMS, One 

Democracy Plaza, Room 820, MSC 4872, 

6701 Democracy Blvd, Bethesda, MD 20892–

4872, 301–594–4953, 

Michael_Bloom@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: July 16, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3585 Filed 7–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Autoimmunity Program 

Project. 

Date: August 14, 2007. 

Time: 3 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Bethesda, MD 20817, (Telephone Conference 

Call). 

Contact Person: Kenneth E. Santora, PhD, 

Scientific Review Administrator, Scientific 

Review Program, NIH/NIAID/DHHS, Room 

3146, 6700B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892, (301) 451–2605, 

ks216i@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

July 17, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3588 Filed 7–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

mstockstill on PROD1PC66 with NOTICES